Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.

Demircan NC, Dane F, Ozturk MA, Babacan NA, Besiroglu M, Kaya S, Ercelep O, Tanrikulu E, Halil S, Koca S, Alan O, Hasanov R, Yumuk PF.

J BUON. 2019 Jul-Aug;24(4):1494-1500.

2.

How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.

Alan O, Kuzhan O, Koca S, Telli TA, Tuylu TB, Ercelep O, Filinte D, Sengul Y, Arikan H, Kaya S, Babacan NA, Dane F, Yumuk PF.

J Oncol Pharm Pract. 2019 Oct 15:1078155219879757. doi: 10.1177/1078155219879757. [Epub ahead of print]

PMID:
31615346
3.

Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.

Kıvrak Salim D, Akın Telli T, Tatlı AM, Kılıçkap S, Yumuk PF.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1137-1145. doi: 10.1007/s00280-019-03839-w. Epub 2019 Apr 9.

PMID:
30972457
4.

Sleep disturbances in patients with lung cancer in Turkey.

Bülbül Y, Özlü T, Arınç S, Akıncı Özyürek B, Günbatar H, Şentürk A, Bahadır A, Özçelik M, Yılmaz U, Akbay MÖ, Sağlam L, Kılıç T, Kırkıl G, Özçelik N, Alizoroğlu D, Argun Barış S, Yavşan DM, Şen HS, Berk S, Acat M, Çakmak G, Yumuk PF, İntepe YS, Toru Ü, Öktem Ayık S, Başyiğit İ, Özkurt S, Mutlu LC, Yaşar Z, Esme H, Erol MM, Oruç Ö, Erdoğan Y, Asker S, Ulaş A, Erol S, Kerget B, Erbaycu AE, Teke T, Beşiroğlu M, Can H, Dallı A, Talay F.

Tuberk Toraks. 2018 Dec;66(4):297-303. doi: 10.5578/tt.67689.

5.

Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.

Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group.

Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30.

PMID:
30377778
6.

Chordoma: a case series and review of the literature.

Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF.

J Med Case Rep. 2018 Aug 27;12(1):239. doi: 10.1186/s13256-018-1784-y. Review.

7.

A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy.

Alan O, Telli TA, Ercelep O, Hasanov R, Simsek ET, Mutis A, Ones T, Kaya H, Yumuk PF.

Curr Probl Cancer. 2019 Aug;43(4):308-311. doi: 10.1016/j.currproblcancer.2018.04.003. Epub 2018 May 9.

PMID:
29880396
8.

Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.

Batirel HF, Metintas M, Caglar HB, Ak G, Yumuk PF, Ahiskali R, Bozkurtlar E, Bekiroglu N, Lacin T, Yildizeli B, Yuksel M.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2724-2733. doi: 10.1016/j.jtcvs.2017.12.131. Epub 2018 Feb 9.

PMID:
29510939
9.

Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer.

Tezcan S, İzzettin FV, Sancar M, Turhal NS, Yumuk PF.

Eur J Hosp Pharm. 2018 Mar;25(e1):e17-e20. doi: 10.1136/ejhpharm-2016-001188. Epub 2017 Mar 10.

10.

Assessment of Palliative Care in Lung Cancer in Turkey.

Bülbül Y, Ozlu T, Arinc S, Ozyurek BA, Gunbatar H, Senturk A, Bahadir A, Ozcelik M, Yilmaz U, Akbay MO, Saglam L, Kilic T, Kirkil G, Ozcelik N, Tatar D, Baris SA, Yavsan DM, Sen HS, Berk S, Acat M, Cakmak G, Yumuk PF, Intepe YS, Toru U, Ayik SO, Basyigit I, Ozkurt S, Mutlu LC, Yasar ZA, Esme H, Erol MM, Oruc O, Erdoğan Y, Asker S, Ulas A, Erol S, Kerget B, Erbaycu AE, Teke T, Beşiroğlu M, Can H, Dalli A, Talay F.

Med Princ Pract. 2017;26(1):50-56. doi: 10.1159/000452801. Epub 2016 Oct 24.

11.

Another adverse effect of vemurafenib: Gingival hyperplasia.

Salman A, Tekin B, Koca S, Akgul Babacan N, Yumuk PF, Ergun T.

J Dermatol. 2016 Jun;43(6):706-7. doi: 10.1111/1346-8138.13248. Epub 2015 Dec 24. No abstract available.

PMID:
26703083
12.

Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.

Batirel HF, Metintas M, Caglar HB, Ak G, Yumuk PF, Yildizeli B, Yuksel M.

J Thorac Cardiovasc Surg. 2016 Feb;151(2):478-84. doi: 10.1016/j.jtcvs.2015.09.121. Epub 2015 Oct 9.

13.

Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?

Ozturk MA, Dane F, Karagoz S, Tural D, Selcukbiricik F, Demirelli F, Buyukunal E, Ozguroglu M, Turna H, Erdamar S, Celikel CA, Bozkurtlar EB, Yumuk PF, Mandel NM, Turhal NS, Serdengecti S.

Hepatogastroenterology. 2015 Jan-Feb;62(137):59-64.

PMID:
25911868
14.

Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.

Iyikesici MS, Basaran G, Dane F, Ekenel M, Yumuk PF, Cabuk D, Teomete M, Turhal NS.

Int J Clin Exp Med. 2014 May 15;7(5):1459-64. eCollection 2014.

15.

Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.

Cabuk D, Basaran G, Teomete M, Dane F, Korkmaz T, Seber S, Telli F, Yumuk PF, Turhal S.

Asian Pac J Cancer Prev. 2014;15(1):117-22.

16.

Bacteraemia caused by Clostridium symbiosum: case report and review of the literature.

Toprak NU, Özcan ET, Pekin T, Yumuk PF, Soyletir G.

Indian J Med Microbiol. 2014 Jan-Mar;32(1):92-4. doi: 10.4103/0255-0857.124343. Review. No abstract available.

17.

Health-related quality of life during postoperative chemoradiotherapy with oral uracil-tegafur and leucovorin in rectal cancer patients.

Ozgen Z, Ozden S, Dane F, Atasoy BM, Akgun Z, Yumuk PF.

Hepatogastroenterology. 2013 May;60(123):533-7.

PMID:
23159353
18.

How do lung cancer specialists follow their patients with stage III non-small cell lung cancer (NSCLC) after definitive treatment? A short report.

Yumuk PF, Mohammed N, Maat AP, Fink C, Marchal B, O'Brien ME.

Eur J Cancer. 2012 Sep;48(14):2163-5. doi: 10.1016/j.ejca.2012.04.006. Epub 2012 May 26.

PMID:
22633748
19.

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.

Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M.

J Neurooncol. 2011 Jul;103(3):585-93. doi: 10.1007/s11060-010-0423-2. Epub 2010 Sep 29.

PMID:
20878446
20.

Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer.

Kaya AO, Buyukberber S, Dane F, Isikdogan A, Ustaalioglu BO, Coskun U, Yumuk PF, Dogu GG, Ozdemir NY, Sevinc A, Gumus M, Ozkan M, Yildiz R, Ozturk B, Yaman E, Benekli M; Anatolian Society of Medical Oncology.

Tumori. 2010 May-Jun;96(3):400-4.

PMID:
20845799
21.

Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey.

Basaran G, Turhal NS, Cabuk D, Yurt N, Yurtseven G, Gumus M, Teomete M, Dane F, Yumuk PF.

Med Oncol. 2011 Jun;28(2):409-15. doi: 10.1007/s12032-010-9463-x. Epub 2010 Mar 20.

PMID:
20306160
22.

Pulmonary toxicity in patients receiving docetaxel chemotherapy.

Yumuk PF, Kefeli U, Ceyhan B, Dane F, Eroglu BT, Gumus M, Cabuk D, Basaran G, Abacioglu U, Turhal NS.

Med Oncol. 2010 Dec;27(4):1381-8. doi: 10.1007/s12032-009-9391-9. Epub 2009 Dec 25.

PMID:
20035385
23.

A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.

Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete M, Turhal NS.

J BUON. 2009 Apr-Jun;14(2):309-11.

24.

Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer.

Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, Turhal NS.

Eur J Cancer Care (Engl). 2009 Mar;18(2):191-4. doi: 10.1111/j.1365-2354.2008.00973.x.

PMID:
19267736
25.

Impact of body mass index on cancer development.

Yumuk PF, Dane F, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Toprak A, Iyikesici S, Basaran G, Turhal NS.

J BUON. 2008 Jan-Mar;13(1):55-9.

26.

Toxicity and feasibility analysis for cisplatin-based concomitant chemoradiotherapy in locally advanced nasopharyngeal carcinoma.

Atasoy BM, Dane F, Yumuk PF, Akgün Z, Turhal NS, Abacioğlu U, Sengöz M.

J BUON. 2008 Jan-Mar;13(1):43-50.

27.

Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival.

Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, Ekenel M, Turhal NS.

Oncology. 2007;72(1-2):111-7. Epub 2007 Nov 15.

PMID:
18025805
28.

Epithelioid hemangioendothelioma with multiple organ involvement.

Celikel C, Yumuk PF, Basaran G, Yildizeli B, Kodalli N, Ahiskali R.

APMIS. 2007 Jul;115(7):881-8. Review.

PMID:
17614859
29.

Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer.

Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z, Mayadagli A, Basaran G, Turhal S, Sengoz M.

J BUON. 2007 Apr-Jun;12(2):203-8.

30.

HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples.

Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H, Barisik N, Turhal NS.

J Exp Clin Cancer Res. 2006 Dec;25(4):515-21.

PMID:
17310842
31.

Limited painful mouth opening.

Güler N, Yumuk PF, Ilguy D, Olgac V, Greer J.

J Oral Maxillofac Surg. 2005 Aug;63(8):1201-5. No abstract available.

PMID:
16094591
32.

Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer.

Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS.

BMC Cancer. 2005 Jul 6;5:71.

33.

What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery?

Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, Turhal S.

Tumori. 2005 Mar-Apr;91(2):168-72.

PMID:
15948546
34.

D-dimer--can it be a marker for malignant gastric lesions?

Aliustaoglu M, Yumuk PF, Gumus M, Ekenel M, Bolukbas F, Bolukbas C, Mutlu N, Basaran G, Avsar E, Turhal NS.

Acta Oncol. 2004;43(8):770-1. No abstract available.

PMID:
15764225
35.

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.

Yumuk PF, Turhal NS, Gumus M, Hatabay NF, Turken O, Ozkan A, Salepci T, Aliustaoglu M, Ahiskali R.

BMC Cancer. 2005 Jan 25;5:10.

36.

Attitude toward genetic testing for cancer risk in Istanbul.

Yumuk PF, Gumus M, Ekenel M, Basaran G, Aliustaoglu M, Topal A, Turhal NS.

Genet Test. 2004 Summer;8(2):169-73.

PMID:
15345115
37.

Does the incidence of anal canal cancers differ in Moslem societies?

Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M, Ekenel M, Basaran G, Turhal NS.

Int J Colorectal Dis. 2005 Jan;20(1):76. Epub 2004 Aug 4. No abstract available.

PMID:
15293063
38.

The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.

Yumuk PF, Aydin SZ, Dane F, Gumus M, Ekenel M, Aliustaoglu M, Karamanoglu A, Sengoz M, Turhal SN.

Int J Colorectal Dis. 2004 Nov;19(6):609-10. Epub 2004 Aug 4. No abstract available.

PMID:
15293062
39.

99m-Tc-MDP-Scintimammography in the evaluation of breast masses or tumor angiogenesis.

Turhal NS, Dane F, Dede F, Gumus M, Yumuk PF, Cakalagaoglu F, Savci D, Karaman M, Gulluoglu B, Turoglu HT.

Anticancer Res. 2004 May-Jun;24(3b):1999-2006.

40.

T-cell lymphoblastic lymphoma presenting with a breast mass.

Yumuk PF, Aydiner A, Topuz E, Cabioglu N, Dogan O.

Leuk Lymphoma. 2004 Apr;45(4):833-6. Review.

PMID:
15160967
41.

Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital.

Yumuk PF, Abacioglu U, Caglar H, Gumus M, Sengoz M, Turhal NS.

J Chemother. 2003 Dec;15(6):603-6.

PMID:
14998088
42.

Port needles: do they need to be removed as frequently in infusional chemotherapy?

Karamanoglu A, Yumuk PF, Gumus M, Ekenel M, Aliustaoglu M, Selimen D, Sengoz M, Turhal NS.

J Infus Nurs. 2003 Jul-Aug;26(4):239-42.

PMID:
12869857

Supplemental Content

Loading ...
Support Center